Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 7/20 | 0.36 |
| ▸ | EEF2K | O00418 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12711161 | 0.84 | NR3C2 (0.34) | CA2ALDH1A1 | |
| SCHEMBL12711160 | 0.82 | HTT (0.38) | CYP3A4CA2ALDH1A1 | |
| SCHEMBL12711157 | 0.82 | ADRB2 (0.38) | MEN1ALDH1A1KMT2AHIF1A | |
| SCHEMBL12711162 | 0.82 | ACP3 (0.37) | CYP3A4 | |
| SCHEMBL12711159 | 0.79 | CYP2C9 (0.30) | CYP3A4ALDH1A1 | |
| SCHEMBL12711151 | 0.78 | TRPA1 (0.45) | GRIA4ALDH1A1KMT2A | |
| SCHEMBL12711171 | 0.78 | TRPA1 (0.45) | GRIA4ALDH1A1KMT2A | |
| SCHEMBL15431784 | 0.78 | CYP3A4 (0.42) | CYP3A4GRIA4EEF2KCES2CES1 | |
| SCHEMBL15022607 | 0.76 | CYP3A4 (0.40) | CYP3A4ALDH1A1CES2CES1HIF1A | |
| SCHEMBL12711158 | 0.75 | HDAC4 (0.38) | MEN1KMT2ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | SNRPB2, SNRPA1, DUT | CYP3A4 4409/4885GRIA4 4460/4885EEF2K 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.